Exclusive Summary

• The mesylate salt form provides a differentiated advantage (better water solubility, faster onset, lower toxicity) over traditional ropivacaine hydrochloride, helping to stand out in a highly competitive alternative market.
• Known for its unique 'sensory-motor separation' and notably lower cardiotoxicity than bupivacaine, it is a first-line agent recommended by global guidelines for labor analgesia and postoperative pain management.
• Relying on China's mature API-to-finished-product supply chain, the product boasts significant cost advantages, offering high margin potential for overseas distributors.
• With over 300 million major surgeries globally per year and the increasing penetration of epidural and local anesthesia, the demand for long-acting anesthetics exhibits robust, rigid growth.